In the pharmaceutical industry, timelines serve as both operational benchmarks and market signals. When sponsors announce trial starts and milestones, the investment community pays close attention. But what happens when behind-the-scenes issues, such as delays in sourcing a comparator drug, throw those timelines off track? At Clinical Services International (CSI), we have seen firsthand how comparator drug sourcing, though often underestimated, can become a critical path depe

We’re incredibly proud to announce that CSI has once again achieved the Platinum EcoVadis rating, for the second year in a row! This places us in the top 1% globally for sustainability, ethics and corporate responsibility. It’s an incredible accomplishment and a testament to the values we live by every day. A huge thank you to our dedicated team for making this possible, your commitment continues to set us apart.

Read our tips to help you reduce the risk associated with comparator sourcing Like all supply chains, comparator sourcing poses substantial risks, such as sourcing comparator drugs, obtaining the correct documentation, supply chain delays and compliance with local and global regulations. With our science-based approach and over 25 years of experience in comparator sourcing, we have a detailed understanding of the risks it brings. Here are three ways you can reduce the risks t

Learn more about local comparator sourcing and the advantages it can bring to clinical trials Comparators are increasingly being used in clinical trials to test the efficacy of investigational medicinal products compared to the existing market product. As the number of clinical trials across the globe grows, the demand for reference drugs, or comparators, is mounting. This demand puts pressure on comparator sourcing partners to source enough comparator products within the req